MNK Opioid-related payouts to less than expected - NYT https://seekingalpha.com/news/3542632 The New York Times reports that lawyers representing U.S. states and cities suing opioid markers and distributors now concede that the prospective payouts will be much less that originally expected.

MNK новость из индустрии: Teva wins first date to market generic Linzess in the USA

SAGE • The FDA's approval of Intra-Cellular Therapies' (ITCI +191.6%) schizophrenia drug bodes well for other companies with therapies for the central nervous system, writes Stifel analyst Paul Matteis. • He points to Sage Therapeutics (SAGE -1.1%), Acadia Pharmaceuticals (ACAD -1.7%), Karuna Therapeutics (KRTX -7.3%), and, to some extent, Biogen (BIIB +0.6%). • The recent approval shows that regulators will "often look at a mixed efficacy package in CNS through a 'glass half full lens'," given that ITCI's drug failed in one of the two Phase 3 studies, he writes.